Literature DB >> 21142023

Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.

Jacqueline N Parker1, Xiaojia Zheng, William Luckett, James M Markert, Kevin A Cassady.   

Abstract

Conditionally replication-competent Herpes Simplex Virus Type 1 (HSV-1) vectors expressing foreign genes have been developed as experimental therapeutic agents. Traditional methods of virus construction, including growth selection based on thymidine kinase gene expression, and color selection based on a reporter gene expression are often time-consuming and relatively inefficient. This review summarizes the various strategies developed in recent years for the rapid and efficient construction of novel conditionally replication-competent mutant HSV expressing multiple foreign genes. Additionally, two new modifications of existing strategies, which have not been previously reported, are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 21142023      PMCID: PMC3034828          DOI: 10.1021/mp100230y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  19 in total

1.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Authors:  J N Parker; G Y Gillespie; C E Love; S Randall; R J Whitley; J M Markert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

2.  Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection.

Authors:  Kevin A Cassady
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes.

Authors:  B C Horsburgh; M M Hubinette; D Qiang; M L MacDonald; F Tufaro
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

4.  Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

Authors:  Elizabeth K Hellums; James M Markert; Jacqueline N Parker; Bin He; Bernard Perbal; Bernard Roizman; Richard J Whitley; Catherine P Langford; Suman Bharara; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

5.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

6.  Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.

Authors:  Jacqueline N Parker; Sreelatha Meleth; Kenneth B Hughes; G Yancey Gillespie; Richard J Whitley; James M Markert
Journal:  Cancer Gene Ther       Date:  2005-04       Impact factor: 5.987

7.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.

Authors:  S Andreansky; B He; J van Cott; J McGhee; J M Markert; G Y Gillespie; B Roizman; R J Whitley
Journal:  Gene Ther       Date:  1998-01       Impact factor: 5.250

8.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors.

Authors:  Y Saeki; T Ichikawa; A Saeki; E A Chiocca; K Tobler; M Ackermann; X O Breakefield; C Fraefel
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

10.  Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo.

Authors:  Michiko Tanaka; Hiroyuki Kagawa; Yuji Yamanashi; Tetsutaro Sata; Yasushi Kawaguchi
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  2 in total

1.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

2.  Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Authors:  David C Gaston; Carl I Odom; Li Li; James M Markert; Justin C Roth; Kevin A Cassady; Richard J Whitley; Jacqueline N Parker
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.